(SIX: SFZN) As announced in May 2015, RAG-Stiftung Beteiligungsgesellschaft mbH based in Essen, Germany, will participate in a privately placed hybrid bond of Siegfried Holding AG in the amount of CHF 60 million in order to finance Siegfried’s acquisition of significant elements of BASF’s pharmaceutical supply business.
The bond was issued on September 29, 2015, and entitles RAG-Stiftung Beteiligungsgesellschaft mbH to convert the amount within 5 years into Siegfried Holding AG shares, which corresponds to a stake in Siegfried of about 7 percent. It is expected that the shares will come from Siegfried Holding AG’s treasury shares, therefore not having a dilutive effect.
Siegfried CEO Rudolf Hanko: “RAG-Stiftung Beteiligungsgesellschaft mbH is a long-term oriented stable partner with a sustainable focus and in full support of the Siegfried Group’s strategy.”
For further information:
Michael Hüsler, CFO
Tel. +41 (0)62 746 11 35
Mobile +41 (0)79 279 94 52
Siegfried Holding AG
Untere Brühlstrasse 4
Tel. +41 (0)62 746 11 11
Fax +41 (0)62 746 11 03
The Siegfried Group is active worldwide in the field of Life Sciences with production facilities located in Switzerland, Germany, China, Malta and in the USA. At the end of 2014, Siegfried reported annual sales of CHF 315 million and employs at the time being approximately 1400 employees. Siegfried Holding AG is listed on the Swiss Exchange (SIX: SFZN).
Siegfried is active in both the primary and secondary production of drugs. The company develops and manufactures active pharmaceutical ingredients for the research-based pharmaceutical industry as well as the corresponding intermediate steps and controlled substances, and provides development and production services for drugs in finished dosage forms including sterile filling.